Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 5 (May)

1. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
   J Clin Oncol, 24(13): 1990-6. [Abstract] [Full-text]
2. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
   J Clin Oncol, 24(13): 1982-9. [Abstract] [Full-text]
3. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases.
   Lancet Oncol, 7(5): 425-30. [Abstract] [Full-text]
4. Regulation of steroid hydroxylase CYP7B1 by androgens and estrogens in prostate cancer LNCaP cells.
   Biochem Biophys Res Commun, 344(2): 540-6. [Abstract] [Full-text]
5. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
   Am J Med, 119(5): 418-25. [Abstract] [Full-text]
6. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer.
   J Cell Biochem, 98(3): 496-503. [Abstract] [Full-text]
7. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence.
   Genes Chromosomes Cancer, 45(7): 702-16. [Abstract] [Full-text]
8. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
   Genes Chromosomes Cancer, 45(7): 639-45. [Abstract] [Full-text]
9. Research with families facing cancer: the challenges of accrual and retention.
   Res Nurs Health, 29(3): 199-211. [Abstract] [Full-text]
10. Telomerase activity in disseminated prostate cancer cells.
    BJU Int, 97(6): 1309-13. [Abstract] [Full-text]
11. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    BJU Int, 97(6): 1300-8. [Abstract] [Full-text]
12. Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, Canada.
    BJU Int, 97(6): 1273-7. [Abstract] [Full-text]
13. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men.
    BJU Int, 97(6): 1190-3. [Abstract] [Full-text]
14. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    BJU Int, 97(6): 1184-9. [Abstract] [Full-text]
15. Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective.
    BJU Int, 97(6): 1179-83. [Abstract] [Full-text]
16. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    BJU Int, 97(6): 1173-8. [Abstract] [Full-text]
17. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    BJU Int, 97(6): 1169-72. [Abstract] [Full-text]
18. Interfering with cell-survival signalling as a treatment strategy for prostate cancer.
    BJU Int, 97(6): 1149-53. [Abstract] [Full-text]
19. Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy.
    Int J Radiat Oncol Biol Phys, 65(2): 595-607. [Abstract] [Full-text]
20. A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT.
    Int J Radiat Oncol Biol Phys, 65(2): 587-94. [Abstract] [Full-text]
21. A gradient feature weighted Minimax algorithm for registration of multiple portal images to 3DCT volumes in prostate radiotherapy.
    Int J Radiat Oncol Biol Phys, 65(2): 535-47. [Abstract] [Full-text]
22. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 65(2): 528-34. [Abstract] [Full-text]
23. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
    Int J Radiat Oncol Biol Phys, 65(2): 364-70. [Abstract] [Full-text]
24. Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy.
    Int J Radiat Oncol Biol Phys, 65(2): 378-87. [Abstract] [Full-text]
25. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 65(2): 358-63. [Abstract] [Full-text]
26. Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 65(2): 347-50. [Abstract] [Full-text]
27. Influence of intrafraction motion on margins for prostate radiotherapy.
    Int J Radiat Oncol Biol Phys, 65(2): 548-53. [Abstract] [Full-text]
28. Bladder filling variation during radiation treatment of prostate cancer: can the use of a bladder ultrasound scanner and biofeedback optimize bladder filling?
    Int J Radiat Oncol Biol Phys, 65(2): 371-7. [Abstract] [Full-text]
29. An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk.
    Int J Radiat Oncol Biol Phys, 65(2): 351-7. [Abstract] [Full-text]
30. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Urology, 67(5): 1084.e15-7. [Abstract] [Full-text]
31. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Urology, 67(5): 1028-32. [Abstract] [Full-text]
32. Ethnicity and determinants of quality of life after prostate cancer treatment.
    Urology, 67(5): 1022-7. [Abstract] [Full-text]
33. Prognostic factors in lymph node-positive prostate cancer.
    Urology, 67(5): 1016-21. [Abstract] [Full-text]
34. Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.
    Urology, 67(5): 1001-6. [Abstract] [Full-text]
35. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy.
    Urology, 67(5): 996-1000. [Abstract] [Full-text]
36. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer.
    Urology, 67(5): 1007-11. [Abstract] [Full-text]
37. Radical perineal prostatectomy for treatment of localized prostate cancer in obese and nonobese patients: a matched control study.
    Urology, 67(5): 990-5. [Abstract] [Full-text]
38. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
    Cancer Cell, 9(5): 367-78. [Abstract] [Full-text]
39. Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications.
    Prostate, 66(9): 954-65. [Abstract] [Full-text]
40. Energy balance alters dunning R3327-H prostate tumor architecture, androgen receptor expression, and nuclear morphometry in rats.
    Prostate, 66(9): 945-53. [Abstract] [Full-text]
41. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7.
    Prostate, 66(9): 966-70. [Abstract] [Full-text]
42. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer.
    Prostate, 66(9): 1005-12. [Abstract] [Full-text]
43. Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.
    Prostate, 66(9): 911-20. [Abstract] [Full-text]
44. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.
    Prostate, 66(9): 971-86. [Abstract] [Full-text]
45. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Prostate, 66(9): 987-95. [Abstract] [Full-text]
46. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
    Prostate, 66(9): 996-1004. [Abstract] [Full-text]
47. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
    Prostate, 66(9): 921-35. [Abstract] [Full-text]
48. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells.
    Prostate, 66(9): 936-44. [Abstract] [Full-text]
49. Loss of PTEN is associated with progression to androgen independence.
    Prostate, 66(9): 895-902. [Abstract] [Full-text]
50. Genetic variation in the COX-2 gene and the association with prostate cancer risk.
    Int J Cancer, 119(3): 668-72. [Abstract] [Full-text]
51. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro.
    Mol Genet Metab, 88(2): 114-22. [Abstract] [Full-text]
52. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
    J Natl Cancer Inst, 98(10): 715-7. [Abstract] [Full-text]
53. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Am J Clin Pathol, 125(5): 675-81. [Abstract] [Full-text]
54. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging.
    Radiology, 239(3): 784-92. [Abstract] [Full-text]
55. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Prostate, 66(10): 1076-81. [Abstract] [Full-text]
56. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Prostate, 66(10): 1070-5. [Abstract] [Full-text]
57. The effects of short-term oral phytoestrogen supplementation on the hypothalamic-pituitary-testicular axis in prostate cancer patients.
    Prostate, 66(10): 1086-91. [Abstract] [Full-text]
58. Protocadherin-PC promotes androgen-independent prostate cancer cell growth.
    Prostate, 66(10): 1100-13. [Abstract] [Full-text]
59. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
    Prostate, 66(10): 1114-23. [Abstract] [Full-text]
60. Germline ATBF1 mutations and prostate cancer risk.
    Prostate, 66(10): 1082-5. [Abstract] [Full-text]
61. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
    Prostate, 66(10): 1092-9. [Abstract] [Full-text]
62. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system.
    Prostate, 66(10): 1037-43. [Abstract] [Full-text]
63. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
    Prostate, 66(10): 1044-51. [Abstract] [Full-text]
64. Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6.
    Prostate, 66(10): 1052-60. [Abstract] [Full-text]
65. Expression and role of Foxa proteins in prostate cancer.
    Prostate, 66(10): 1013-28. [Abstract] [Full-text]
66. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
    DNA Cell Biol, 25(5): 287-94. [Abstract] [Full-text]
67. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.
    Cancer Chemother Pharmacol, 58(3): 354-60. [Abstract] [Full-text]
68. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Cancer Immunol Immunother, 55(9): 1033-42. [Abstract] [Full-text]
69. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.
    Clin Chem, 52(6): 1089-95. [Abstract] [Full-text]
70. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner.
    Oncogene, 25(22): 3139-49. [Abstract] [Full-text]
71. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
    J Clin Oncol, 24(16): 2513-9. [Abstract] [Full-text]
72. Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo.
    Biochem Biophys Res Commun, 345(3): 1207-14. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.